Autres langues GSK plc

Actions

GSK

GB00BN7SWP63

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:01 21/09/2026			Varia. 5j.	Varia. 1 janv.
1 911,00 ^GBX	+1,78%		+7,94%	+4,74%

18:06	Les actions européennes cotées aux États-Unis sous forme d'American Depositary Receipts progressent lors de la séance de lundi	MT
15:53	Le secteur pharmaceutique mise sur l'IA pour réduire ses coûts et ses délais	RE

Autres langues

18:06	European Equities Traded in the US as American depositary Receipts Rise in Monday Trading
15:53	Pharma sector doubles down on AI to slash costs, timelines
13:20	Vault Ventures rebrands as Sentry 7, appoints new CEO
18/09	European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading
17/09	ViiV Healthcare Partners with Prevention Access Campaign (PAC) to Celebrate 10 Years of U=U and Look to The Future
16/09	Pharma sector doubles down on AI to slash costs, timelines
16/09	Europese beurzen hoger in afwachting van Fed-besluit
16/09	UK inflation rises; Barratt cuts completions outlook
16/09	AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down
15/09	GSK plc : Priced for the storm, being built for thereafter
15/09	European Stocks Close Lower in Tuesday Trading; Energy, Defense Stocks Rise as Oil, Bond Yields Rise
15/09	Global markets live: Amazon, BofA, ExxonMobil, OpenAI, SpaceX…
15/09	GSK Upgraded to Buy as Berenberg Notes Pipeline Momentum; Price Target Raised
15/09	Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to Advance HIV Response in the U.S.
15/09	GSK to Acquire Experimental Blood Cancer Therapy From Chimagen in $750 Million Deal
15/09	Europese beurzen lager rond lunchtijd
15/09	Berenberg likes GSK; Deutsche Bank lifts Astra
15/09	GSK agrees up to USD750 million deal for blood cancer-targeting drug
15/09	GSK Agrees to Buy Potential Blood Cancer Treatment for Up to $750 Million
15/09	GSK kauft für bis zu 750 Mio Dollar Rechte an Antikörper von Chimagen
15/09	GSK in T-cell deal; Kier puts brakes on Property arm
15/09	GSK to Buy Antibody Treatment From Chimagen for Up to $750 Million
15/09	GSK to Acquire Chimagen Biosciences' T-Cell Engager Program for Up to $750 Million
15/09	GSK : to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
15/09	GSK strikes up to $750 million deal for cancer-targeting drug